Crestline Management, LP Puma Biotechnology, Inc. Transaction History

Crestline Management, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.29 - $7.4 $4,538 - $7,829	1,058 Added 3.04%	35,832 $189,000
Q4 2023 Feb 12, 2024	BUY	$2.23 - $4.49 $4,761 - $9,586	2,135 Added 6.54%	34,774 $150,000
Q2 2023 Aug 14, 2023	BUY	$2.6 - $3.58 $1,963 - $2,702	755 Added 2.37%	32,639 $115,000
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $7,487 - $16,330	3,388 Added 11.89%	31,884 $98,000
Q4 2022 Feb 13, 2023	BUY	$2.12 - $5.08 $616 - $1,478	291 Added 1.03%	28,496 $120,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.3 $600 - $1,207	-366 Reduced 1.28%	28,205 $80,000
Q1 2022 May 16, 2022	BUY	$2.13 - $3.24 $60,856 - $92,570	28,571 New	28,571 $82,000
Q3 2019 Nov 13, 2019	SELL	$8.75 - $12.85 $280,000 - $411,200	-32,000 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$12.3 - $35.76 $393,600 - $1.14 Million	32,000 New	32,000 $407,000
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $747,038 - $1.09 Million	-18,132 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $875,775 - $1.24 Million	18,132 New	18,132 $1.07 Million
Q3 2017 Nov 14, 2017	SELL	$72.0 - $119.75 $1.13 Million - $1.88 Million	-15,685 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	15,685	15,685 $1.37 Million

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $123M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.